Intestinal Permeability in Non-alcoholic Fatty LIVER Disease: The Gut-liver Axis

被引：28
|
作者：
Scarpellini, E. [1 ]
Lupo, M. [2 ]
Iegri, C. [2 ]
Gasbarrini, A. [3 ]
De Santis, A. [2 ]
Tack, J. [1 ]
机构：
[1] KULeuven, TARGID, Leuven, Belgium
[2] Sapienza Univ Rome, Umberto I Univ Hosp, Div Gastroenterol, Rome, Italy
[3] Gemelli Univ Hosp, Internal Med & Gastroenterol Div, Rome, Italy
来源：
REVIEWS ON RECENT CLINICAL TRIALS | 2014年 / 9卷 / 03期
关键词：
Intestinal permeability; zonulin-1; claudin; nafld; nash; lipopolysaccharide;
D O I：
10.2174/1574887109666141216104334
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The gut-liver axis model has helped to explain the liver steatosis (NAFLD) and steatohepatitis (NASH) etiopathogenesis. The discovery of a key role for an altered intestinal permeability (IP) in this pathophysioligcal framework has closed the link between gut lumen antigenic/toxic substances and systemic and liver inflammation in NAFLD and obesity, metabolic syndrome. Recent evidence from the literature show how IP can be modulated by several non-pharmacological and pharmacological agents and be the target for future preventive and curative treatment of NAFLD and NASH. In this review we describe the concept of IP, its ultrastructural basis, its role in the NALFD pathophysiology and emerging evidence on non-pharmacological and pharmacological agents able to favourably modulate it.
引用
收藏
页码：141 / 147
页数：7
相关论文
共 50 条
  • [41] Treatment regimens for non-alcoholic fatty liver disease
    Lam, Brian P.
    Younossi, Zobair M.
    ANNALS OF HEPATOLOGY, 2009, 8 : S51 - S59
  • [42] Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
    Khneizer, Gebran
    Rizvi, Syed
    Gawrieh, Samer
    DIABETES: FROM RESEARCH TO CLINICAL PRACTICE, VOL 4, 2021, 1307 : 417 - 440
  • [43] Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
    Valenzuela-Vallejo, Laura
    Sanoudou, Despina
    Mantzoros, Christos S.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [44] A Comprehensive Review on Non-Alcoholic Fatty Liver Disease
    Sahu, Prerna
    Chhabra, Pratyaksh
    Mehendale, Ashok M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [45] Non-alcoholic fatty liver disease: A sign of systemic disease
    Reccia, Isabella
    Kumar, Jayant
    Akladios, Cherif
    Virdis, Francesco
    Pai, Madhava
    Habib, Nagy
    Spalding, Duncan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2017, 72 : 94 - 108
  • [46] Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV
    Jürgen Kurt Rockstroh
    Current HIV/AIDS Reports, 2017, 14 : 47 - 53
  • [47] Intestinal microbiota and non alcoholic fatty liver disease
    Cassard, Anne-Marie
    Houron, Camille
    Ciocan, Dragos
    NUTRITION CLINIQUE ET METABOLISME, 2020, 34 (02): : 130 - 140
  • [48] The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
    Ni, Yiming
    Lu, Mengna
    Xu, Yuan
    Wang, Qixue
    Gu, Xinyi
    Li, Ying
    Zhuang, Tongxi
    Xia, Chenyi
    Zhang, Ting
    Gou, Xiao-jun
    Zhou, Mingmei
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [49] Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents
    Tokuhara, Daisuke
    FRONTIERS IN NUTRITION, 2021, 8
  • [50] Treatment of Non-Alcoholic Fatty Liver Disease
    Scherer, Antonia
    Dufour, Jean-Francois
    DIGESTIVE DISEASES, 2016, 34 : 27 - 31
12345